MiMedx initiated with a Buy at Lake Street

Lake Street analyst Brooks O’Neil initiated coverage of MiMedx with a Buy rating and $12 price target. MiMedx “put the past in the past” after years of turmoil by appointing Joe Capper as CEO in January of last year, says the firm, which calls Capper “a strong and experienced executive we know from his days leading BioTelemetry.” Capper has reinforced the company’s commitment to technological investment in both advanced wound care and surgical recovery, says the firm, which thinks MiMedx is positioned on a path of sustained growth with Capper now in command, a solid core business and a strong financial position.